Anti-EGFR CAR-T cell therapy (Cellular Biomedicine Group)

N/A

Report date: 2022/12/03 20:00:24

Base Information

Drug NameAnti-EGFR CAR-T cell therapy (Cellular Biomedicine Group)
Drug Alias NameCART-EGFRAnti-EGFR CAR-transduced T-cell therapy - Cellular Biomedicine GroupCART-HER1Anti-EGFR CARChimeric-EGFR-antigen-receptor-modified-T-cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesCellular Biomedicine (Shanghai) Co LtdPeople'S Liberation Army General Hospital Military Service
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPla General HospitalCellular Biomedicine (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A